Assessment of cardiovascular (CV) toxicity by providers in advanced prostate cancer (PCa) patients (pts) on novel hormonal therapy (NHT).

125 Background: Addition of NHT, including Abiraterone, Enzalutamide, Apalutamide, and Darolutamide, to androgen deprivation therapy in patients with advanced PCa demonstrated improved survival in large randomized controlled trials. However, NHTs are associated with development of metabolic syndrome and CV toxicity. Treatment related adverse events (TRAEs) may include hypertension (HTN), hyperglycemia, atrial fibrillation, myocardial infarction (MI), congestive heart failure (CHF), and stroke. As such, monitoring for these toxicities by treating providers is essential. Cardio-oncology is an emerging field that addresses CV needs of cancer pts and fosters collaboration between oncologists and cardiologists. Methods: This is a retrospective analysis of 92 pts with advanced PCa, who initiated an NHT in 2022 at the University of California Irvine. Medical records were analyzed for various metrics relating to CV risk assessment performed by treating providers. Results: Pts of 11 different providers, including medical and urologic oncology, were examined. Characteristics of the study population at NHT start are described (Table). Within specific study population subgroups outlined, corresponding provider interventions within 3 months of NHT start are also listed. Conclusions: In this dataset of pts with pre-existing features of metabolic syndrome and CV risk factors at NHT start, only a minority had screening for hyperglycemia, hyperlipidemia, and cardiac dysfunction as well as had counseling about appropriate nutrition or referred to cardiology. Provider education about NHT-related TRAEs and emphasis on early screening for CV toxicity is key. Characteristics of the study population and corresponding provider interventions. Pt characteristic at NHT start % of pts Had lipid panel checked (%) Had hemoglobin A1C checked (%) Seen by cardiology before NHT start (%) Referred to cardiology post NHT start (%) Had documented counseling about nutrition (%) Had echocardiogram (%) Body mass index (BMI) 25.0 - 29.9 50.0 26.1 32.6 23.9 6.5 10.9 23.9 BMI ≥30 21.7 40.0 40.0 35.0 0.0 10.0 30.0 Former or active smoker 41.3 42.1 42.1 23.7 5.3 5.3 34.2 Hx of HTN 69.6 29.7 42.2 29.7 3.1 7.8 23.4 On ≥2 blood pressure (BP) agents 29.3 48.1 55.6 40.7 3.7 3.7 40.7 Hx of hyperlipidemia 64.1 30.5 35.6 28.8 1.7 8.5 25.4 On a statin 51.1 31.9 34.0 29.8 2.1 8.5 27.7 Hx of MI 20.7 36.8 36.8 52.6 0.0 5.3 31.6 Hx of CHF 9.8 44.4 77.8 55.6 11.1 0.0 55.6 Hx of arrhythmia 20.7 42.1 57.9 57.9 0.0 0.0 31.6 Hx of stroke <jats:td colspa